Comparison · NCT02424851-sae
Arm A (BBD) vs Arm B (BTD): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A (BBD) vs Arm B (BTD): serious adverse events. Trial comparisons, record NCT02424851-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02424851-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.688 | 0.444 | 0.858 | wilson | |
| Risk in group 2 | 0.6 | 0.357 | 0.802 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0875 | -0.229 | 0.384 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.675 | 1.94 | log | |
| Odds ratio, group 1 over group 2 | 1.47 | 0.335 | 6.43 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm A (BBD) than on Arm B (BTD) | 11.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A (BBD) | Bortezomib, Bendamustine and Dexamethasone~Bortezomib: 1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib~Bendamustine: 60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)~Dexamethasone: 40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle | 11 | 16 | EG000 |
| Group 2 | Arm B (BTD) | Thalidomide, Bendamustine and Dexamethasone~Thalidomide: 100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)~Bendamustine: 60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)~Dexamethasone: 40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle | 9 | 15 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 4 years, 2 months.
Source ClinicalTrials.gov
Trial
- Title
- Optimising Renal Outcome in Myeloma Renal Failure
- NCT number
- NCT02424851
- Phases
- PHASE2
- Conditions
- Multiple Myeloma, Chronic Kidney Disease
- Interventions
- Bortezomib, Thalidomide, Bendamustine, Dexamethasone
- Lead sponsor
- Oxford University Hospitals NHS Trust
- Results first posted
- 2022-01-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02424851?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02424851-sae